Molbio Diagnostics Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Molbio Diagnostics Limited's is gearing up for its market debut with an Initial Public Offering aggregating TBD. The fresh issue component ofTBD will bolster the company's balance sheet.
The IPO features a competitive price band of ₹770 to ₹810 per share, with the minimum investment requirement set at 18 shares. This structure aims to attract diverse investor participation across market segments.
The public subscription window is slated to open on Aug 07, 2026 and close on Aug 11, 2026. Following the subscription period, allotment will be finalized on Aug 12, 2026, with the stock listing anticipated on Aug 14, 2026 at the NSE, BSE exchange.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Innovative Diagnostic Technology: Company nu flagship molecular testing platform rapid ane accurate diagnosis aape che, je healthcare sector ma strong differentiation create kare che.
- Recurring Consumable Revenue: Devices install thaya pachhi test kits ni regular demand ave che, je company ne stable ane repeat income aape che.
- Strong Financial Growth: Recent years ma revenue ane profit ma fast growth joi male che, je business scalability ane demand darshave che.
- High Dependence on Government Orders: Revenue no moto hissa government ane institutional clients mathi ave che, je policy changes thi impact thai shake che.
- Product Concentration Risk: Company nu major revenue limited diagnostic tests (especially TB related) par dependent che, je diversification risk create kare che.
- Working Capital Intensive: Inventory ane operations maintain karva ma heavy working capital joiye, je cash flow par pressure muki shake che.
- Sriram Natarajan
- Dr. Chandrasekhar Bhaskaran Nair
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Exxora Trading LLP
Molbio Diagnostics Limited
Kfin Technologies Limited